Orion reports Nubeqa cut metastasis or death risk by 58% in prostate cancer trial

Orion Corporation announced positive Phase III results for Nubeqa (darolutamide) combined with androgen deprivation therapy and radiation therapy, reducing the risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence. The data were presented at the ESMO 2026 congress.

Detected & updated continuously · Source: Nebula